Announcements, press, and milestones.

Proud to share that our Founding Managing Partner Nisa Leung has been featured in Mergermarket APAC’s spotlight on APAC dealmaking leaders. Thank you to ION Analytics for highlighting the diverse paths shaping leadership in M&A, investing, law, and capital markets.

#APAC #VC #VentureCapital #MergersAndAcquisitions #Healthcare #Biotech

We are delighted to welcome Franck Le Deu to Aulis as Venture Partner. Franck will help build the Life Sciences practice in China and Asia and bridging the West and the East and give strategic advice to the fund as well as our portfolio companies.

Aulis Capital is pleased to announce our investment in EpiBiologics’ $107M Series B financing. EpiBiologics is advancing a next-generation protein degradation pipeline and platform that targets extracellular membrane and soluble proteins. The Company’s proprietary EpiTAC platform is a modular bispecific antibody system that enables targeted degradation of disease-driving extracellular proteins in a tissue-specific manner.

With this financing, EpiBiologics will advance their pipeline of novel bispecific antibodies to selectively degrade disease-driving membrane and soluble targets in oncology and immunology. EpiBiologics aims to develop first-in-class and best-in-class targeted therapies across multiple therapeutic areas, including oncology and immunology.

#EpiBiologics #EGFR #Lungcancer #NSCLC #HNSCC